Btobioinnovation.com 

Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com 

SPECIAL REPORT #21.22

European Biotechnology Companies

According to your own database, there are currently 57 European biotechnology companies listed on NASDAQ.

The origins of these companies are as follow: 13 from the U.K., 8 from Ireland and from France, 7 from Germany, 6 from Denmark, the Netherlands and from Switzerland, 2 from Belgium and 1 from Sweden.

The listing of these companies and their origin does not provide any meaningful information about their impact in the biopharmaceutical industry.

An analysis of their current portfolio and their market capitalisation (as of September 30, 2021) is a far better indicator of their value and their performance.

Of the 57 companies listed, only 20 have a market capitalisation of $1 billion and above with expectedly BioNTech (which by the way is not listed in Europe) from Germany leading the pack with a current value of $66 billion. The second largest company is Genmab from Denmark with a market value of $29 billion, and the third one Horizon Therapeutics from the U.K. with a value of $25 billion.

When looking in more depth at these stock market performers the listing and the rating of the top 20 companies become far more informative in which countries the highest value has been generated.

Germany positions 4 out of 7. Ireland 4 out of 8, Denmark 3 out of 6, Belgium 2 out of 2, Switzerland 2 out of 6, the U.K. 2 out of 13, the Netherlands 1 out of 6, and France 1 out of 8.

This report is not to claim that all European life science companies need to move to NASDAQ, in the US, to raise significant venture capital. The recent success story by Oxford Nanopore, which raised net proceeds of $450 million on the London exchange and has reached a peak value of $6.84 billion is a clear example of what can be achieved in Europe. “This will be seen as a vote of confidence for the London Stock Exchange as a worthy launch pad for both tech and pharmaceutical companies, particularly given the NASDAQ’s dominance in this space” Hargreaves Landsdown analyst Susannah Streeter said on September 30, 2021.

Paris, October 21, 2021

This document has been prepared by btobioinnovation and is provided to you for information purposes only.  The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change.  btobioinnovation has no obligation to update its opinions or the information in this document.